TC BioPharm’s cell banks have been developed as a resource for clinical development of cost-effective, safe and efficacious cancer treatments and ultimately, the ability to treat more patients. These T cell banks provide TC BioPharm with core technology to develop a deep portfolio of next-generation CAR-T products directed against a wide variety of different cancer types, both hematological and solid tumors. Our cell bank project is supported by funding from the European Union’s Horizon 2020 (H2020) Research and Innovation program via a €4million grant, the largest such EU award to any UK company for the development of a healthcare therapeutic product. Cellular material is collected and stored from healthy donors, providing a source for TC BioPharm to manufacture next-generation ‘off-the-shelf’ GDT cell therapies for future clinical product development.
Advantages of Using Allogeneic Cell Banks:
- Hundreds of patients can be treated from a single donor.
- Campaign manufacturing allows for lower costs and consequently increased patient access and decreased burden on healthcare systems.
- Donors are selected to ensure that the banked cells have the ideal drug properties for GDT cell-based products.
- Reproducible manufacturing allows for consistent safety and potency.
These cell banks allow us to develop better products to reach more patients.